GW Pharmaceuticals PLC Notice of Results (1622D)
27 January 2015 - 6:01PM
UK Regulatory
TIDMGWP
RNS Number : 1622D
GW Pharmaceuticals PLC
27 January 2015
GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host
Conference Call on 4 February, 2015
London, UK, 27 January 2015: GW Pharmaceuticals plc (Nasdaq:
GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company
focused on discovering, developing and commercializing novel
therapeutics from its proprietary cannabinoid product platform,
will report on 4 February, 2015 its first quarter financial results
for the period ending 31 December, 2014. GW will also host a
conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.
Conference call information will be provided in the financial
results press release. A replay of the call will also be available
through the Company's website (www.gwpharm.com) shortly after the
call.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R) , which is approved for
the treatment of spasticity due to multiple sclerosis in 27
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer. GW is also advancing an orphan drug program
in the field of childhood epilepsy with a focus on Epidiolex(R) ,
which is in Phase 2/3 clinical development for the treatment of
Dravet syndrome and which is also expected to enter Phase 3
clinical trials in the treatment of Lennox-Gastaut syndrome. GW has
a deep pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 clinical development for
glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For
further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations
(U.S.) 917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen
(UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900
Peel Hunt LLP (UK NOMAD) +44 20 7418 8900
James Steel / Clare Terlouw
This information is provided by RNS
The company news service from the London Stock Exchange
END
NOREQLFLEFFZBBF
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about GW Pharm. (London Stock Exchange): 0 recent articles
More Gw Pharmaceuticals News Articles